Recently, Sun and Wang showed that a combined therapy of SPHK inhibitors and all-trans retinoic acid (ATRA), which has been described as limited to a treatment for CML, exert synergistic effects to inhibit proliferation in CML cells (85). The gene discussed is SPHK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.